MiR-34a-5p promotes the multi-drug resistance of osteosarcoma by targeting the CD117 gene

Oncotarget

Volumn 7, Issue 19, 2016, Pages 28420-28434

  Pu, Youguang ^a   Zhao, Fangfang ^a   Wang, Haiyan ^a   Cai, Wenjing ^b   Gao, Jin ^a   Li, Yinpeng ^c   Cai, Shanbao ^a  

^a ANHUI PROVINCIAL HOSPITAL   (China)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c XINXIANG MEDICAL UNIVERSITY   (China)

Author keywords

CD117; MiR 34a 5p; Multi drug resistance; Osteosarcoma

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; ACTIVATING TRANSCRIPTION FACTOR 3; ACTIVATING TRANSCRIPTION FACTOR 4; CISPLATIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; METHOTREXATE; MICRORNA; MICRORNA 34A 5P; MITOGEN ACTIVATED PROTEIN KINASE; MYOCYTE ENHANCER FACTOR 2; PROTEIN P53; STEM CELL FACTOR RECEPTOR; UNCLASSIFIED DRUG; MIRN34 MICRORNA, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER RESISTANCE; CD117 GENE; CONTROLLED STUDY; GENE EXPRESSION; GENE FUNCTION; GENE REPRESSION; GENE TARGETING; GENETIC ASSOCIATION; GENETIC MARKER; INTRACELLULAR SIGNALING; MALE; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; OSTEOSARCOMA; OSTEOSARCOMA CELL LINE; TUMOR XENOGRAFT; BIOSYNTHESIS; BONE TUMOR; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; TUMOR CELL LINE;

BONE NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; OSTEOSARCOMA; PROTO-ONCOGENE PROTEINS C-KIT;

EID: 84968919940     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8546     Document Type: Article

References (43)

1. Pillai RS, Bhattacharyya SN, Filipowicz W. Repression of protein synthesis by miRNAs: how many mechanisms? Trends in cell biology. 2007; 17:118-126.
2. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR. MicroRNA expression profiles classify human cancers. Nature. 2005; 435:834-838.
3. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proceedings of the National Academy of Sciences of the United States of America. 2006; 103:2257-2261.
4. Allen KE, Weiss GJ. Resistance may not be futile: microRNA biomarkers for chemoresistance and potential therapeutics. Molecular cancer therapeutics. 2010; 9:3126-3136.
5. He H, Ni J, Huang J. Molecular mechanisms of chemoresistance in osteosarcoma (Review). Oncology letters. 2014; 7:1352-1362.
6. Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, Yuen ST, Chan TL, Kwong DL, Au GK, Liu CG, Calin GA, Croce CM, Harris CC. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. Jama. 2008; 299:425-436.
7. Yang L, Li N, Wang H, Jia X, Wang X, Luo J. Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance. Oncology reports. 2012; 28:592-600.
8. Song B, Wang Y, Xi Y, Kudo K, Bruheim S, Botchkina GI, Gavin E, Wan Y, Formentini A, Kornmann M, Fodstad O, Ju J. Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene. 2009; 28:4065-4074.
9. Nakatani F, Ferracin M, Manara MC, Ventura S, Del Monaco V, Ferrari S, Alberghini M, Grilli A, Knuutila S, Schaefer KL, Mattia G, Negrini M, Picci P, Serra M, Scotlandi K. miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemosensitivity and malignancy. The Journal of pathology. 2012; 226:796-805.
10. Gao J, Li N, Dong Y, Li S, Xu L, Li X, Li Y, Li Z, Ng SS, Sung JJ, Shen L, Yu J. miR-34a-5p suppresses colorectal cancer metastasis and predicts recurrence in patients with stage II/III colorectal cancer. Oncogene. 2015; 34:4142-4152.
11. Hermeking H. p53 enters the microRNA world. Cancer cell. 2007; 12:414-418.
12. Yamakuchi M, Lowenstein CJ. MiR-34, SIRT1 and p53: the feedback loop. Cell Cycle. 2009; 8:712-715.
13. Wu J, Wu G, Lv L, Ren YF, Zhang XJ, Xue YF, Li G, Lu X, Sun Z, Tang KF. MicroRNA-34a inhibits migration and invasion of colon cancer cells via targeting to Fra-1. Carcinogenesis. 2012; 33:519-528.
14. Ji Q, Hao X, Meng Y, Zhang M, Desano J, Fan D, Xu L. Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC cancer. 2008; 8:266.
15. Li N, Fu H, Tie Y, Hu Z, Kong W, Wu Y, Zheng X. miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. Cancer letters. 2009; 275:44-53.
16. Gallardo E, Navarro A, Vinolas N, Marrades RM, Diaz T, Gel B, Quera A, Bandres E, Garcia-Foncillas J, Ramirez J, Monzo M. miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis. 2009; 30:1903-1909.
17. Botter SM, Neri D, Fuchs B. Recent advances in osteosarcoma. Current opinion in pharmacology. 2014; 16:15-23.
18. Yang J, Zhang W. New molecular insights into osteosarcoma targeted therapy. Current opinion in oncology. 2013; 25:398-406.
19. Ni S, Huang D, Chen X, Huang J, Kong Y, Xu Y, Du X, Sheng W. c-kit gene mutation and CD117 expression in human anorectal melanomas. Human pathology. 2012; 43:801-807.
20. Went PT, Dirnhofer S, Bundi M, Mirlacher M, Schraml P, Mangialaio S, Dimitrijevic S, Kononen J, Lugli A, Simon R,Sauter G. Prevalence of KIT expression in human tumors. Journal of clinical oncology. 2004; 22:4514-4522.
21. Pon JR, Marra MA. MEF2 transcription factors: developmental regulators and emerging cancer genes. Oncotarget. 2016; 7:2297-2331. doi: 10.18632/oncotarget. 6223.
22. Siemens H, Jackstadt R, Kaller M, Hermeking H. Repression of c-Kit by p53 is mediated by miR-34 and is associated with reduced chemoresistance, migration and stemness. Oncotarget. 2013; 4:1399-1415. doi:10.18632/oncotarget.1202.
23. Montojo J, Zuberi K, Rodriguez H, Bader GD, Morris Q. GeneMANIA: Fast gene network construction and function prediction for Cytoscape. F1000Research. 2014; 3:153.
24. Kalathur RK, Pinto JP, Hernandez-Prieto MA, Machado RS, Almeida D, Chaurasia G, Futschik ME. UniHI 7: an enhanced database for retrieval and interactive analysis of human molecular interaction networks. Nucleic acids research. 2014; 42(Database issue):D408-414.
25. Ma K, He Y, Zhang H, Fei Q, Niu D, Wang D, Ding X, Xu H, Chen X, Zhu J. DNA methylation-regulated miR-193a-3p dictates resistance of hepatocellular carcinoma to 5-fluorouracil via repression of SRSF2 expression. The Journal of biological chemistry. 2012; 287:5639-5649.
26. Lv L, Deng H, Li Y, Zhang C, Liu X, Liu Q, Zhang D, Wang L, Pu Y, Zhang H, He Y, Wang Y, Yu Y, Yu T, Zhu J. The DNA methylation-regulated miR-193a-3p dictates the multi-chemoresistance of bladder cancer via repression of SRSF2/PLAU/HIC2 expression. Cell death & disease. 2014; 5:e1402.
27. Deng H, Lv L, Li Y, Zhang C, Meng F, Pu Y, Xiao J, Qian L, Zhao W, Liu Q, Zhang D, Wang Y, Zhang H, He Y, Zhu J. miR-193a-3p regulates the multi-drug resistance of bladder cancer by targeting the LOXL4 gene and the Oxidative Stress pathway. Molecular cancer. 2014; 13:234.
28. Gao J, Li N, Dong Y, Li S, Xu L, Li X, Li Y, Li Z, Ng SS, Sung JJ, Shen L, Yu J. miR-34a-5p suppresses colorectal cancer metastasis and predicts recurrence in patients with stage II/III colorectal cancer. Oncogene. 2015; 34:4142-4152.
29. Zhao H, Ma B, Wang Y, Han T, Zheng L, Sun C, Liu T, Zhang Y, Qiu X, Fan Q. miR-34a inhibits the metastasis of osteosarcoma cells by repressing the expression of CD44. Oncology reports. 2013; 29:1027-1036.
30. Anderson DM, Lyman SD, Baird A, Wignall JM, Eisenman J, Rauch C, March CJ, Boswell HS, Gimpel SD, Cosman D, et al. Molecular cloning of mast cell growth factor, a hematopoietin that is active in both membrane bound and soluble forms. Cell. 1990; 63:235-243.
31. Ikeda H, Kanakura Y, Tamaki T, Kuriu A, Kitayama H, Ishikawa J, Kanayama Y, Yonezawa T, Tarui S, Griffin JD. Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells. Blood. 1991; 78:2962-2968.
32. Mahzouni P, Jafari M. The study of CD117 expression in glial tumors and its relationship with the tumor-type and grade. Journal of research in medical sciences: the official journal of Isfahan University of Medical Sciences. 2012; 17:159-163.
33. Montone KT, van Belle P, Elenitsas R, Elder DE. Protooncogene c-kit expression in malignant melanoma: protein loss with tumor progression. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc. 1997; 10:939-944.
34. Krystal GW, Hines SJ, Organ CP. Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. Cancer research. 1996; 56:370-376.
35. Hines SJ, Organ C, Kornstein MJ, Krystal GW. Coexpression of the c-kit and stem cell factor genes in breast carcinomas. Cell growth & differentiation. 1995; 6:769-779.
36. Arber DA, Tamayo R, Weiss LM. Paraffin section detection of the c-kit gene product (CD117) in human tissues: value in the diagnosis of mast cell disorders. Human pathology. 1998; 29:498-504.
37. Gibson PC, Cooper K. CD117 (KIT): a diverse protein with selective applications in surgical pathology. Advances in anatomic pathology. 2002; 9:65-69.
38. Sattler M, Salgia R. Targeting c-Kit mutations: basic science to novel therapies. Leukemia research. 2004; 28 Suppl 1:S11-20.
39. Adhikari AS, Agarwal N, Wood BM, Porretta C, Ruiz B, Pochampally RR, Iwakuma T. CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance. Cancer research. 2010; 70:4602-4612.
40. Su Y, Luo X, He BC, Wang Y, Chen L, Zuo GW, Liu B, Bi Y, Huang J, Zhu GH, He Y, Kang Q, Luo J, Shen J, Chen J, Jin X, et al. Establishment and characterization of a new highly metastatic human osteosarcoma cell line. Clinical & experimental metastasis. 2009; 26:599-610.
41. Tarazona S, Garcia-Alcalde F, Dopazo J, Ferrer A, Conesa A. Differential expression in RNA-seq: a matter of depth. Genome research. 2011; 21:2213-2223.
42. Heiser LM, Sadanandam A, Kuo WL, Benz SC, Goldstein TC, Ng S, Gibb WJ, Wang NJ, Ziyad S, Tong F, Bayani N, Hu Z, Billig JI, Dueregger A, Lewis S, Jakkula L, et al. Subtype and pathway specific responses to anticancer compounds in breast cancer. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109:2724-2729.
43. Andrisano V, Bartolini M, Gotti R, Cavrini V, Felix G. Determination of inhibitors' potency (IC50) by a direct high-performance liquid chromatographic method on an immobilised acetylcholinesterase column. Journal of chromatography B, Biomedical sciences and applications. 2001; 753:375-383.